BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 7655380)

  • 21. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N; Hoffknecht M; Hänel M; Krüger W; Zeller W; Stockschläder M; de Wit M; Weh HJ; Kabisch H; Erttmann R; Zander AR
    Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
    Lancet JE; Rapoport AP; Brasacchio R; Eberly S; Raubertas RF; Linder T; Muhs A; Duerst RE; Abboud CN; Packman CH; DiPersio JF; Constine LS; Rowe JM; Liesveld JL
    Bone Marrow Transplant; 1998 Aug; 22(3):265-71. PubMed ID: 9720740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
    Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C
    Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
    Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
    Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
    Burns LJ; Daniels KA; McGlave PB; Miller WJ; Ramsay NK; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group.
    Borgmann A; Hartmann R; Schmid H; Klingebiel T; Ebell W; Göbel U; Peters C; Gadner H; Henze G
    Bone Marrow Transplant; 1995 Apr; 15(4):515-21. PubMed ID: 7655375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.